Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab

European Journal of Haematology

Volumn 81, Issue 6, 2008, Pages 448-453

  Oki, Yasuhiro ^a   Yamamoto, Kazuhito ^a   Kato, Harumi ^a   Kuwatsuka, Yachiyo ^a   Taji, Hirofumi ^a   Kagami, Yoshitoyo ^a   Morishima, Yasuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Absolute lymphocyte count; Diffuse large B cell lymphoma; Prognostic factor; Rituximab

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL; SYMPTOM; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREDNISONE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; VINCRISTINE;

EID: 56649121692     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01129.x     Document Type: Article

References (10)

1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998 339 : 1506 14.
2. Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006 134 : 596 601.
3. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007 21 : 2227 30.
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 329 : 987 94.
5. Kaplan EL, Meire P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 53 : 457 81.
6. Cox MC, Nofroni I, Laverde G, et al. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2008 141 : 265 8.
7. Talaulikar D, Choudhury A, Shadbolt B, Brown M. Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma 2008 49 : 959 64.
8. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003 101 : 4279 84.
9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 346 : 235 42.
10. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 7 : 379 91.